nodes	percent_of_prediction	percent_of_DWPC	metapath
Trandolapril—Lisinopril—systemic scleroderma	0.323	1	CrCtD
Trandolapril—ACE—systemic scleroderma	0.168	1	CbGaD
Trandolapril—ACE—Lisinopril—systemic scleroderma	0.068	0.329	CbGbCtD
Trandolapril—Enalapril—Captopril—systemic scleroderma	0.0527	0.226	CrCrCtD
Trandolapril—ACE—Captopril—systemic scleroderma	0.0509	0.246	CbGbCtD
Trandolapril—CES1—Mycophenolate mofetil—systemic scleroderma	0.0401	0.194	CbGbCtD
Trandolapril—Fosinopril—Lisinopril—systemic scleroderma	0.0285	0.122	CrCrCtD
Trandolapril—SLC15A1—Lisinopril—systemic scleroderma	0.0273	0.132	CbGbCtD
Trandolapril—Moexipril—Lisinopril—systemic scleroderma	0.0214	0.0919	CrCrCtD
Trandolapril—SLC15A1—Captopril—systemic scleroderma	0.0204	0.0988	CbGbCtD
Trandolapril—Spirapril—Lisinopril—systemic scleroderma	0.0185	0.0794	CrCrCtD
Trandolapril—Cilazapril—Lisinopril—systemic scleroderma	0.0185	0.0794	CrCrCtD
Trandolapril—Enalapril—Lisinopril—systemic scleroderma	0.0174	0.0745	CrCrCtD
Trandolapril—Ramipril—Lisinopril—systemic scleroderma	0.0174	0.0745	CrCrCtD
Trandolapril—Nateglinide—Lisinopril—systemic scleroderma	0.0155	0.0664	CrCrCtD
Trandolapril—Quinapril—Lisinopril—systemic scleroderma	0.0147	0.0631	CrCrCtD
Trandolapril—Aspartame—Lisinopril—systemic scleroderma	0.0147	0.0631	CrCrCtD
Trandolapril—Benazepril—Lisinopril—systemic scleroderma	0.014	0.0601	CrCrCtD
Trandolapril—ACE—forelimb zeugopod—systemic scleroderma	0.00341	0.22	CbGeAlD
Trandolapril—ACE—pulmonary artery—systemic scleroderma	0.00255	0.164	CbGeAlD
Trandolapril—ACE—skeletal joint—systemic scleroderma	0.00226	0.146	CbGeAlD
Trandolapril—ACE—umbilical vein—systemic scleroderma	0.00168	0.109	CbGeAlD
Trandolapril—ACE—artery—systemic scleroderma	0.000944	0.061	CbGeAlD
Trandolapril—ACE—endothelium—systemic scleroderma	0.000798	0.0515	CbGeAlD
Trandolapril—ACE—blood vessel—systemic scleroderma	0.000736	0.0475	CbGeAlD
Trandolapril—CES1—connective tissue—systemic scleroderma	0.000567	0.0366	CbGeAlD
Trandolapril—CES1—digestive system—systemic scleroderma	0.000409	0.0264	CbGeAlD
Trandolapril—SLC15A1—digestive system—systemic scleroderma	0.00038	0.0245	CbGeAlD
Trandolapril—ACE—connective tissue—systemic scleroderma	0.000377	0.0244	CbGeAlD
Trandolapril—ACE—smooth muscle tissue—systemic scleroderma	0.000345	0.0223	CbGeAlD
Trandolapril—CES1—lung—systemic scleroderma	0.000342	0.0221	CbGeAlD
Trandolapril—ACE—digestive system—systemic scleroderma	0.000272	0.0176	CbGeAlD
Trandolapril—Fosinopril—ACE—systemic scleroderma	0.000233	0.135	CrCbGaD
Trandolapril—ACE—lung—systemic scleroderma	0.000228	0.0147	CbGeAlD
Trandolapril—SLC15A2—lung—systemic scleroderma	0.000198	0.0128	CbGeAlD
Trandolapril—Perindopril—ACE—systemic scleroderma	0.00019	0.11	CrCbGaD
Trandolapril—Spirapril—ACE—systemic scleroderma	0.000188	0.109	CrCbGaD
Trandolapril—Moexipril—ACE—systemic scleroderma	0.00018	0.104	CrCbGaD
Trandolapril—Quinapril—ACE—systemic scleroderma	0.000168	0.0971	CrCbGaD
Trandolapril—Lisinopril—ACE—systemic scleroderma	0.000168	0.0971	CrCbGaD
Trandolapril—Cilazapril—ACE—systemic scleroderma	0.000168	0.0971	CrCbGaD
Trandolapril—Ramipril—ACE—systemic scleroderma	0.000162	0.0941	CrCbGaD
Trandolapril—Benazepril—ACE—systemic scleroderma	0.000146	0.0845	CrCbGaD
Trandolapril—Enalapril—ACE—systemic scleroderma	0.000123	0.0713	CrCbGaD
Trandolapril—Anorexia—Lisinopril—systemic scleroderma	3.39e-05	0.000646	CcSEcCtD
Trandolapril—Gastrointestinal pain—Leflunomide—systemic scleroderma	3.38e-05	0.000645	CcSEcCtD
Trandolapril—Constipation—Mycophenolic acid—systemic scleroderma	3.37e-05	0.000643	CcSEcCtD
Trandolapril—Palpitations—Mycophenolate mofetil—systemic scleroderma	3.37e-05	0.000643	CcSEcCtD
Trandolapril—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	3.35e-05	0.000639	CcSEcCtD
Trandolapril—Hyperglycaemia—Prednisone—systemic scleroderma	3.35e-05	0.000638	CcSEcCtD
Trandolapril—Cough—Mycophenolate mofetil—systemic scleroderma	3.33e-05	0.000635	CcSEcCtD
Trandolapril—Hypotension—Lisinopril—systemic scleroderma	3.32e-05	0.000633	CcSEcCtD
Trandolapril—Dizziness—Captopril—systemic scleroderma	3.32e-05	0.000633	CcSEcCtD
Trandolapril—Liver function test abnormal—Methotrexate—systemic scleroderma	3.31e-05	0.000632	CcSEcCtD
Trandolapril—Depression—Prednisone—systemic scleroderma	3.3e-05	0.000629	CcSEcCtD
Trandolapril—Urticaria—Leflunomide—systemic scleroderma	3.28e-05	0.000627	CcSEcCtD
Trandolapril—Body temperature increased—Leflunomide—systemic scleroderma	3.27e-05	0.000623	CcSEcCtD
Trandolapril—Abdominal pain—Leflunomide—systemic scleroderma	3.27e-05	0.000623	CcSEcCtD
Trandolapril—Acute coronary syndrome—Prednisone—systemic scleroderma	3.26e-05	0.000622	CcSEcCtD
Trandolapril—Feeling abnormal—Mycophenolic acid—systemic scleroderma	3.25e-05	0.00062	CcSEcCtD
Trandolapril—Chest pain—Mycophenolate mofetil—systemic scleroderma	3.25e-05	0.000619	CcSEcCtD
Trandolapril—Myalgia—Mycophenolate mofetil—systemic scleroderma	3.25e-05	0.000619	CcSEcCtD
Trandolapril—Arthralgia—Mycophenolate mofetil—systemic scleroderma	3.25e-05	0.000619	CcSEcCtD
Trandolapril—Myocardial infarction—Prednisone—systemic scleroderma	3.24e-05	0.000619	CcSEcCtD
Trandolapril—Breast disorder—Methotrexate—systemic scleroderma	3.24e-05	0.000618	CcSEcCtD
Trandolapril—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	3.24e-05	0.000617	CcSEcCtD
Trandolapril—Anxiety—Mycophenolate mofetil—systemic scleroderma	3.23e-05	0.000617	CcSEcCtD
Trandolapril—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	3.23e-05	0.000616	CcSEcCtD
Trandolapril—Hypersensitivity—Azathioprine—systemic scleroderma	3.22e-05	0.000615	CcSEcCtD
Trandolapril—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	3.22e-05	0.000615	CcSEcCtD
Trandolapril—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	3.22e-05	0.000615	CcSEcCtD
Trandolapril—Insomnia—Lisinopril—systemic scleroderma	3.21e-05	0.000613	CcSEcCtD
Trandolapril—Discomfort—Mycophenolate mofetil—systemic scleroderma	3.21e-05	0.000612	CcSEcCtD
Trandolapril—Paraesthesia—Lisinopril—systemic scleroderma	3.19e-05	0.000609	CcSEcCtD
Trandolapril—Vomiting—Captopril—systemic scleroderma	3.19e-05	0.000608	CcSEcCtD
Trandolapril—Dry mouth—Mycophenolate mofetil—systemic scleroderma	3.17e-05	0.000606	CcSEcCtD
Trandolapril—Dyspnoea—Lisinopril—systemic scleroderma	3.17e-05	0.000604	CcSEcCtD
Trandolapril—Rash—Captopril—systemic scleroderma	3.16e-05	0.000603	CcSEcCtD
Trandolapril—Dermatitis—Captopril—systemic scleroderma	3.16e-05	0.000603	CcSEcCtD
Trandolapril—Somnolence—Lisinopril—systemic scleroderma	3.16e-05	0.000602	CcSEcCtD
Trandolapril—Headache—Captopril—systemic scleroderma	3.14e-05	0.000599	CcSEcCtD
Trandolapril—Dyspepsia—Lisinopril—systemic scleroderma	3.13e-05	0.000597	CcSEcCtD
Trandolapril—Body temperature increased—Mycophenolic acid—systemic scleroderma	3.12e-05	0.000595	CcSEcCtD
Trandolapril—Abdominal pain—Mycophenolic acid—systemic scleroderma	3.12e-05	0.000595	CcSEcCtD
Trandolapril—Oedema—Mycophenolate mofetil—systemic scleroderma	3.11e-05	0.000594	CcSEcCtD
Trandolapril—Infection—Mycophenolate mofetil—systemic scleroderma	3.09e-05	0.00059	CcSEcCtD
Trandolapril—Decreased appetite—Lisinopril—systemic scleroderma	3.09e-05	0.000589	CcSEcCtD
Trandolapril—Eosinophilia—Methotrexate—systemic scleroderma	3.07e-05	0.000586	CcSEcCtD
Trandolapril—Gastrointestinal disorder—Lisinopril—systemic scleroderma	3.07e-05	0.000585	CcSEcCtD
Trandolapril—Fatigue—Lisinopril—systemic scleroderma	3.06e-05	0.000584	CcSEcCtD
Trandolapril—Shock—Mycophenolate mofetil—systemic scleroderma	3.06e-05	0.000584	CcSEcCtD
Trandolapril—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	3.05e-05	0.000582	CcSEcCtD
Trandolapril—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	3.05e-05	0.000581	CcSEcCtD
Trandolapril—Hypersensitivity—Leflunomide—systemic scleroderma	3.05e-05	0.000581	CcSEcCtD
Trandolapril—Pancreatitis—Methotrexate—systemic scleroderma	3.04e-05	0.00058	CcSEcCtD
Trandolapril—Constipation—Lisinopril—systemic scleroderma	3.04e-05	0.00058	CcSEcCtD
Trandolapril—Tachycardia—Mycophenolate mofetil—systemic scleroderma	3.04e-05	0.000579	CcSEcCtD
Trandolapril—Skin disorder—Mycophenolate mofetil—systemic scleroderma	3.02e-05	0.000577	CcSEcCtD
Trandolapril—Bradycardia—Prednisone—systemic scleroderma	3.02e-05	0.000577	CcSEcCtD
Trandolapril—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	3.01e-05	0.000574	CcSEcCtD
Trandolapril—Diarrhoea—Azathioprine—systemic scleroderma	2.99e-05	0.000571	CcSEcCtD
Trandolapril—Nausea—Captopril—systemic scleroderma	2.98e-05	0.000568	CcSEcCtD
Trandolapril—Anorexia—Mycophenolate mofetil—systemic scleroderma	2.97e-05	0.000566	CcSEcCtD
Trandolapril—Asthenia—Leflunomide—systemic scleroderma	2.97e-05	0.000566	CcSEcCtD
Trandolapril—Hallucination—Prednisone—systemic scleroderma	2.95e-05	0.000564	CcSEcCtD
Trandolapril—Pancytopenia—Methotrexate—systemic scleroderma	2.94e-05	0.000562	CcSEcCtD
Trandolapril—Feeling abnormal—Lisinopril—systemic scleroderma	2.93e-05	0.000558	CcSEcCtD
Trandolapril—Pruritus—Leflunomide—systemic scleroderma	2.92e-05	0.000558	CcSEcCtD
Trandolapril—Connective tissue disorder—Prednisone—systemic scleroderma	2.92e-05	0.000557	CcSEcCtD
Trandolapril—Hypotension—Mycophenolate mofetil—systemic scleroderma	2.91e-05	0.000555	CcSEcCtD
Trandolapril—Gastrointestinal pain—Lisinopril—systemic scleroderma	2.9e-05	0.000554	CcSEcCtD
Trandolapril—Neutropenia—Methotrexate—systemic scleroderma	2.9e-05	0.000553	CcSEcCtD
Trandolapril—Dizziness—Azathioprine—systemic scleroderma	2.89e-05	0.000552	CcSEcCtD
Trandolapril—Upper respiratory tract infection—Methotrexate—systemic scleroderma	2.88e-05	0.00055	CcSEcCtD
Trandolapril—Erectile dysfunction—Methotrexate—systemic scleroderma	2.86e-05	0.000545	CcSEcCtD
Trandolapril—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	2.84e-05	0.000541	CcSEcCtD
Trandolapril—Photosensitivity reaction—Methotrexate—systemic scleroderma	2.83e-05	0.00054	CcSEcCtD
Trandolapril—Asthenia—Mycophenolic acid—systemic scleroderma	2.83e-05	0.00054	CcSEcCtD
Trandolapril—Diarrhoea—Leflunomide—systemic scleroderma	2.83e-05	0.00054	CcSEcCtD
Trandolapril—Urticaria—Lisinopril—systemic scleroderma	2.82e-05	0.000538	CcSEcCtD
Trandolapril—Insomnia—Mycophenolate mofetil—systemic scleroderma	2.81e-05	0.000537	CcSEcCtD
Trandolapril—Abdominal pain—Lisinopril—systemic scleroderma	2.81e-05	0.000536	CcSEcCtD
Trandolapril—Body temperature increased—Lisinopril—systemic scleroderma	2.81e-05	0.000536	CcSEcCtD
Trandolapril—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	2.79e-05	0.000533	CcSEcCtD
Trandolapril—Pruritus—Mycophenolic acid—systemic scleroderma	2.79e-05	0.000532	CcSEcCtD
Trandolapril—Vomiting—Azathioprine—systemic scleroderma	2.78e-05	0.000531	CcSEcCtD
Trandolapril—Eye disorder—Prednisone—systemic scleroderma	2.77e-05	0.000529	CcSEcCtD
Trandolapril—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	2.77e-05	0.000529	CcSEcCtD
Trandolapril—Somnolence—Mycophenolate mofetil—systemic scleroderma	2.77e-05	0.000528	CcSEcCtD
Trandolapril—Infestation—Methotrexate—systemic scleroderma	2.76e-05	0.000527	CcSEcCtD
Trandolapril—Infestation NOS—Methotrexate—systemic scleroderma	2.76e-05	0.000527	CcSEcCtD
Trandolapril—Drowsiness—Methotrexate—systemic scleroderma	2.76e-05	0.000527	CcSEcCtD
Trandolapril—Rash—Azathioprine—systemic scleroderma	2.76e-05	0.000527	CcSEcCtD
Trandolapril—Dermatitis—Azathioprine—systemic scleroderma	2.76e-05	0.000526	CcSEcCtD
Trandolapril—Depression—Methotrexate—systemic scleroderma	2.76e-05	0.000526	CcSEcCtD
Trandolapril—Flushing—Prednisone—systemic scleroderma	2.76e-05	0.000526	CcSEcCtD
Trandolapril—Headache—Azathioprine—systemic scleroderma	2.74e-05	0.000523	CcSEcCtD
Trandolapril—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	2.74e-05	0.000523	CcSEcCtD
Trandolapril—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	2.74e-05	0.000523	CcSEcCtD
Trandolapril—Dizziness—Leflunomide—systemic scleroderma	2.73e-05	0.000522	CcSEcCtD
Trandolapril—Renal failure—Methotrexate—systemic scleroderma	2.72e-05	0.000518	CcSEcCtD
Trandolapril—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	2.71e-05	0.000516	CcSEcCtD
Trandolapril—Diarrhoea—Mycophenolic acid—systemic scleroderma	2.7e-05	0.000515	CcSEcCtD
Trandolapril—Angiopathy—Prednisone—systemic scleroderma	2.69e-05	0.000514	CcSEcCtD
Trandolapril—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	2.69e-05	0.000513	CcSEcCtD
Trandolapril—Immune system disorder—Prednisone—systemic scleroderma	2.68e-05	0.000512	CcSEcCtD
Trandolapril—Constipation—Mycophenolate mofetil—systemic scleroderma	2.66e-05	0.000508	CcSEcCtD
Trandolapril—Arrhythmia—Prednisone—systemic scleroderma	2.65e-05	0.000506	CcSEcCtD
Trandolapril—Sweating—Methotrexate—systemic scleroderma	2.65e-05	0.000506	CcSEcCtD
Trandolapril—Vomiting—Leflunomide—systemic scleroderma	2.63e-05	0.000501	CcSEcCtD
Trandolapril—Alopecia—Prednisone—systemic scleroderma	2.62e-05	0.000501	CcSEcCtD
Trandolapril—Hypersensitivity—Lisinopril—systemic scleroderma	2.62e-05	0.000499	CcSEcCtD
Trandolapril—Hepatobiliary disease—Methotrexate—systemic scleroderma	2.61e-05	0.000499	CcSEcCtD
Trandolapril—Dizziness—Mycophenolic acid—systemic scleroderma	2.61e-05	0.000498	CcSEcCtD
Trandolapril—Epistaxis—Methotrexate—systemic scleroderma	2.61e-05	0.000497	CcSEcCtD
Trandolapril—Rash—Leflunomide—systemic scleroderma	2.61e-05	0.000497	CcSEcCtD
Trandolapril—Dermatitis—Leflunomide—systemic scleroderma	2.6e-05	0.000497	CcSEcCtD
Trandolapril—Mental disorder—Prednisone—systemic scleroderma	2.6e-05	0.000496	CcSEcCtD
Trandolapril—Nausea—Azathioprine—systemic scleroderma	2.6e-05	0.000496	CcSEcCtD
Trandolapril—Headache—Leflunomide—systemic scleroderma	2.59e-05	0.000494	CcSEcCtD
Trandolapril—Malnutrition—Prednisone—systemic scleroderma	2.58e-05	0.000493	CcSEcCtD
Trandolapril—Agranulocytosis—Methotrexate—systemic scleroderma	2.58e-05	0.000492	CcSEcCtD
Trandolapril—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	2.56e-05	0.000489	CcSEcCtD
Trandolapril—Asthenia—Lisinopril—systemic scleroderma	2.55e-05	0.000486	CcSEcCtD
Trandolapril—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	2.54e-05	0.000486	CcSEcCtD
Trandolapril—Pruritus—Lisinopril—systemic scleroderma	2.51e-05	0.000479	CcSEcCtD
Trandolapril—Vomiting—Mycophenolic acid—systemic scleroderma	2.51e-05	0.000478	CcSEcCtD
Trandolapril—Rash—Mycophenolic acid—systemic scleroderma	2.49e-05	0.000474	CcSEcCtD
Trandolapril—Dermatitis—Mycophenolic acid—systemic scleroderma	2.48e-05	0.000474	CcSEcCtD
Trandolapril—Hepatitis—Methotrexate—systemic scleroderma	2.48e-05	0.000473	CcSEcCtD
Trandolapril—Urticaria—Mycophenolate mofetil—systemic scleroderma	2.47e-05	0.000472	CcSEcCtD
Trandolapril—Headache—Mycophenolic acid—systemic scleroderma	2.47e-05	0.000471	CcSEcCtD
Trandolapril—Pharyngitis—Methotrexate—systemic scleroderma	2.46e-05	0.00047	CcSEcCtD
Trandolapril—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	2.46e-05	0.000469	CcSEcCtD
Trandolapril—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	2.46e-05	0.000469	CcSEcCtD
Trandolapril—Nausea—Leflunomide—systemic scleroderma	2.46e-05	0.000468	CcSEcCtD
Trandolapril—Urinary tract disorder—Methotrexate—systemic scleroderma	2.45e-05	0.000468	CcSEcCtD
Trandolapril—Urethral disorder—Methotrexate—systemic scleroderma	2.43e-05	0.000464	CcSEcCtD
Trandolapril—Diarrhoea—Lisinopril—systemic scleroderma	2.43e-05	0.000464	CcSEcCtD
Trandolapril—Ill-defined disorder—Prednisone—systemic scleroderma	2.4e-05	0.000458	CcSEcCtD
Trandolapril—Visual impairment—Methotrexate—systemic scleroderma	2.39e-05	0.000456	CcSEcCtD
Trandolapril—Anaemia—Prednisone—systemic scleroderma	2.39e-05	0.000456	CcSEcCtD
Trandolapril—Agitation—Prednisone—systemic scleroderma	2.38e-05	0.000453	CcSEcCtD
Trandolapril—Angioedema—Prednisone—systemic scleroderma	2.36e-05	0.000451	CcSEcCtD
Trandolapril—Dizziness—Lisinopril—systemic scleroderma	2.35e-05	0.000448	CcSEcCtD
Trandolapril—Erythema multiforme—Methotrexate—systemic scleroderma	2.35e-05	0.000448	CcSEcCtD
Trandolapril—Nausea—Mycophenolic acid—systemic scleroderma	2.34e-05	0.000447	CcSEcCtD
Trandolapril—Malaise—Prednisone—systemic scleroderma	2.33e-05	0.000445	CcSEcCtD
Trandolapril—Vertigo—Prednisone—systemic scleroderma	2.32e-05	0.000443	CcSEcCtD
Trandolapril—Eye disorder—Methotrexate—systemic scleroderma	2.32e-05	0.000442	CcSEcCtD
Trandolapril—Syncope—Prednisone—systemic scleroderma	2.32e-05	0.000442	CcSEcCtD
Trandolapril—Tinnitus—Methotrexate—systemic scleroderma	2.31e-05	0.000441	CcSEcCtD
Trandolapril—Cardiac disorder—Methotrexate—systemic scleroderma	2.3e-05	0.000439	CcSEcCtD
Trandolapril—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	2.29e-05	0.000437	CcSEcCtD
Trandolapril—Loss of consciousness—Prednisone—systemic scleroderma	2.27e-05	0.000433	CcSEcCtD
Trandolapril—Vomiting—Lisinopril—systemic scleroderma	2.26e-05	0.000431	CcSEcCtD
Trandolapril—Angiopathy—Methotrexate—systemic scleroderma	2.25e-05	0.00043	CcSEcCtD
Trandolapril—Immune system disorder—Methotrexate—systemic scleroderma	2.24e-05	0.000428	CcSEcCtD
Trandolapril—Rash—Lisinopril—systemic scleroderma	2.24e-05	0.000427	CcSEcCtD
Trandolapril—Dermatitis—Lisinopril—systemic scleroderma	2.24e-05	0.000427	CcSEcCtD
Trandolapril—Mediastinal disorder—Methotrexate—systemic scleroderma	2.24e-05	0.000427	CcSEcCtD
Trandolapril—Asthenia—Mycophenolate mofetil—systemic scleroderma	2.23e-05	0.000426	CcSEcCtD
Trandolapril—Headache—Lisinopril—systemic scleroderma	2.23e-05	0.000425	CcSEcCtD
Trandolapril—Pruritus—Mycophenolate mofetil—systemic scleroderma	2.2e-05	0.00042	CcSEcCtD
Trandolapril—Myalgia—Prednisone—systemic scleroderma	2.2e-05	0.00042	CcSEcCtD
Trandolapril—Arthralgia—Prednisone—systemic scleroderma	2.2e-05	0.00042	CcSEcCtD
Trandolapril—Anxiety—Prednisone—systemic scleroderma	2.19e-05	0.000418	CcSEcCtD
Trandolapril—Alopecia—Methotrexate—systemic scleroderma	2.19e-05	0.000418	CcSEcCtD
Trandolapril—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	2.19e-05	0.000417	CcSEcCtD
Trandolapril—Discomfort—Prednisone—systemic scleroderma	2.17e-05	0.000415	CcSEcCtD
Trandolapril—Mental disorder—Methotrexate—systemic scleroderma	2.17e-05	0.000415	CcSEcCtD
Trandolapril—Malnutrition—Methotrexate—systemic scleroderma	2.16e-05	0.000412	CcSEcCtD
Trandolapril—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	2.13e-05	0.000406	CcSEcCtD
Trandolapril—Dysgeusia—Methotrexate—systemic scleroderma	2.12e-05	0.000404	CcSEcCtD
Trandolapril—Nausea—Lisinopril—systemic scleroderma	2.11e-05	0.000403	CcSEcCtD
Trandolapril—Oedema—Prednisone—systemic scleroderma	2.11e-05	0.000402	CcSEcCtD
Trandolapril—Infection—Prednisone—systemic scleroderma	2.1e-05	0.0004	CcSEcCtD
Trandolapril—Back pain—Methotrexate—systemic scleroderma	2.09e-05	0.000399	CcSEcCtD
Trandolapril—Shock—Prednisone—systemic scleroderma	2.08e-05	0.000396	CcSEcCtD
Trandolapril—Nervous system disorder—Prednisone—systemic scleroderma	2.07e-05	0.000395	CcSEcCtD
Trandolapril—Tachycardia—Prednisone—systemic scleroderma	2.06e-05	0.000393	CcSEcCtD
Trandolapril—Dizziness—Mycophenolate mofetil—systemic scleroderma	2.06e-05	0.000393	CcSEcCtD
Trandolapril—Skin disorder—Prednisone—systemic scleroderma	2.05e-05	0.000391	CcSEcCtD
Trandolapril—Hyperhidrosis—Prednisone—systemic scleroderma	2.04e-05	0.000389	CcSEcCtD
Trandolapril—Anorexia—Prednisone—systemic scleroderma	2.01e-05	0.000384	CcSEcCtD
Trandolapril—Ill-defined disorder—Methotrexate—systemic scleroderma	2e-05	0.000382	CcSEcCtD
Trandolapril—Anaemia—Methotrexate—systemic scleroderma	2e-05	0.000381	CcSEcCtD
Trandolapril—Vomiting—Mycophenolate mofetil—systemic scleroderma	1.98e-05	0.000378	CcSEcCtD
Trandolapril—Rash—Mycophenolate mofetil—systemic scleroderma	1.96e-05	0.000374	CcSEcCtD
Trandolapril—Dermatitis—Mycophenolate mofetil—systemic scleroderma	1.96e-05	0.000374	CcSEcCtD
Trandolapril—Headache—Mycophenolate mofetil—systemic scleroderma	1.95e-05	0.000372	CcSEcCtD
Trandolapril—Malaise—Methotrexate—systemic scleroderma	1.95e-05	0.000372	CcSEcCtD
Trandolapril—Vertigo—Methotrexate—systemic scleroderma	1.94e-05	0.00037	CcSEcCtD
Trandolapril—Leukopenia—Methotrexate—systemic scleroderma	1.93e-05	0.000369	CcSEcCtD
Trandolapril—Musculoskeletal discomfort—Prednisone—systemic scleroderma	1.92e-05	0.000367	CcSEcCtD
Trandolapril—Insomnia—Prednisone—systemic scleroderma	1.91e-05	0.000364	CcSEcCtD
Trandolapril—Paraesthesia—Prednisone—systemic scleroderma	1.89e-05	0.000361	CcSEcCtD
Trandolapril—Cough—Methotrexate—systemic scleroderma	1.88e-05	0.00036	CcSEcCtD
Trandolapril—Dyspepsia—Prednisone—systemic scleroderma	1.86e-05	0.000354	CcSEcCtD
Trandolapril—Nausea—Mycophenolate mofetil—systemic scleroderma	1.85e-05	0.000353	CcSEcCtD
Trandolapril—Chest pain—Methotrexate—systemic scleroderma	1.84e-05	0.000351	CcSEcCtD
Trandolapril—Myalgia—Methotrexate—systemic scleroderma	1.84e-05	0.000351	CcSEcCtD
Trandolapril—Arthralgia—Methotrexate—systemic scleroderma	1.84e-05	0.000351	CcSEcCtD
Trandolapril—Decreased appetite—Prednisone—systemic scleroderma	1.83e-05	0.00035	CcSEcCtD
Trandolapril—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	1.83e-05	0.000348	CcSEcCtD
Trandolapril—Fatigue—Prednisone—systemic scleroderma	1.82e-05	0.000347	CcSEcCtD
Trandolapril—Discomfort—Methotrexate—systemic scleroderma	1.82e-05	0.000347	CcSEcCtD
Trandolapril—Constipation—Prednisone—systemic scleroderma	1.8e-05	0.000344	CcSEcCtD
Trandolapril—Infection—Methotrexate—systemic scleroderma	1.75e-05	0.000334	CcSEcCtD
Trandolapril—Feeling abnormal—Prednisone—systemic scleroderma	1.74e-05	0.000332	CcSEcCtD
Trandolapril—Nervous system disorder—Methotrexate—systemic scleroderma	1.73e-05	0.00033	CcSEcCtD
Trandolapril—Thrombocytopenia—Methotrexate—systemic scleroderma	1.73e-05	0.000329	CcSEcCtD
Trandolapril—Gastrointestinal pain—Prednisone—systemic scleroderma	1.72e-05	0.000329	CcSEcCtD
Trandolapril—Skin disorder—Methotrexate—systemic scleroderma	1.71e-05	0.000327	CcSEcCtD
Trandolapril—Hyperhidrosis—Methotrexate—systemic scleroderma	1.7e-05	0.000325	CcSEcCtD
Trandolapril—Anorexia—Methotrexate—systemic scleroderma	1.68e-05	0.000321	CcSEcCtD
Trandolapril—Urticaria—Prednisone—systemic scleroderma	1.68e-05	0.00032	CcSEcCtD
Trandolapril—Abdominal pain—Prednisone—systemic scleroderma	1.67e-05	0.000318	CcSEcCtD
Trandolapril—Body temperature increased—Prednisone—systemic scleroderma	1.67e-05	0.000318	CcSEcCtD
Trandolapril—Hypotension—Methotrexate—systemic scleroderma	1.65e-05	0.000314	CcSEcCtD
Trandolapril—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	1.61e-05	0.000306	CcSEcCtD
Trandolapril—Insomnia—Methotrexate—systemic scleroderma	1.59e-05	0.000304	CcSEcCtD
Trandolapril—Paraesthesia—Methotrexate—systemic scleroderma	1.58e-05	0.000302	CcSEcCtD
Trandolapril—Dyspnoea—Methotrexate—systemic scleroderma	1.57e-05	0.0003	CcSEcCtD
Trandolapril—Somnolence—Methotrexate—systemic scleroderma	1.57e-05	0.000299	CcSEcCtD
Trandolapril—Hypersensitivity—Prednisone—systemic scleroderma	1.55e-05	0.000297	CcSEcCtD
Trandolapril—Dyspepsia—Methotrexate—systemic scleroderma	1.55e-05	0.000296	CcSEcCtD
Trandolapril—Decreased appetite—Methotrexate—systemic scleroderma	1.53e-05	0.000292	CcSEcCtD
Trandolapril—Gastrointestinal disorder—Methotrexate—systemic scleroderma	1.52e-05	0.00029	CcSEcCtD
Trandolapril—Fatigue—Methotrexate—systemic scleroderma	1.52e-05	0.00029	CcSEcCtD
Trandolapril—Asthenia—Prednisone—systemic scleroderma	1.51e-05	0.000289	CcSEcCtD
Trandolapril—Pruritus—Prednisone—systemic scleroderma	1.49e-05	0.000285	CcSEcCtD
Trandolapril—Feeling abnormal—Methotrexate—systemic scleroderma	1.45e-05	0.000277	CcSEcCtD
Trandolapril—Diarrhoea—Prednisone—systemic scleroderma	1.44e-05	0.000275	CcSEcCtD
Trandolapril—Gastrointestinal pain—Methotrexate—systemic scleroderma	1.44e-05	0.000275	CcSEcCtD
Trandolapril—Urticaria—Methotrexate—systemic scleroderma	1.4e-05	0.000267	CcSEcCtD
Trandolapril—Dizziness—Prednisone—systemic scleroderma	1.39e-05	0.000266	CcSEcCtD
Trandolapril—Body temperature increased—Methotrexate—systemic scleroderma	1.39e-05	0.000266	CcSEcCtD
Trandolapril—Abdominal pain—Methotrexate—systemic scleroderma	1.39e-05	0.000266	CcSEcCtD
Trandolapril—Vomiting—Prednisone—systemic scleroderma	1.34e-05	0.000256	CcSEcCtD
Trandolapril—Rash—Prednisone—systemic scleroderma	1.33e-05	0.000254	CcSEcCtD
Trandolapril—Dermatitis—Prednisone—systemic scleroderma	1.33e-05	0.000254	CcSEcCtD
Trandolapril—Headache—Prednisone—systemic scleroderma	1.32e-05	0.000252	CcSEcCtD
Trandolapril—Hypersensitivity—Methotrexate—systemic scleroderma	1.3e-05	0.000248	CcSEcCtD
Trandolapril—Asthenia—Methotrexate—systemic scleroderma	1.26e-05	0.000241	CcSEcCtD
Trandolapril—Nausea—Prednisone—systemic scleroderma	1.25e-05	0.000239	CcSEcCtD
Trandolapril—Pruritus—Methotrexate—systemic scleroderma	1.25e-05	0.000238	CcSEcCtD
Trandolapril—Diarrhoea—Methotrexate—systemic scleroderma	1.21e-05	0.00023	CcSEcCtD
Trandolapril—Dizziness—Methotrexate—systemic scleroderma	1.17e-05	0.000222	CcSEcCtD
Trandolapril—Vomiting—Methotrexate—systemic scleroderma	1.12e-05	0.000214	CcSEcCtD
Trandolapril—Rash—Methotrexate—systemic scleroderma	1.11e-05	0.000212	CcSEcCtD
Trandolapril—Dermatitis—Methotrexate—systemic scleroderma	1.11e-05	0.000212	CcSEcCtD
Trandolapril—Headache—Methotrexate—systemic scleroderma	1.1e-05	0.000211	CcSEcCtD
Trandolapril—Nausea—Methotrexate—systemic scleroderma	1.05e-05	0.0002	CcSEcCtD
